Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
NEISSERIA MENINGITIDIS C TETANUS TOXOID
Baxter Healthcare Limited
Suspension for Injection
2001-07-13
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT NeisVac-C 0.5 ml Suspension for injection in pre-filled syringe. Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains: _Neisseria meningitidis _group C (strain C11) polysaccharide (de-O-acetylated)...10 micrograms conjugated to tetanus toxoid…………….............................................…....10-20 micrograms adsorbed on aluminium hydroxide, hydrated.…………...……………………..…0.5 mg Al 3+ For a full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. A semi-opaque white to off-white suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS NeisVac-C is indicated for active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by _Neisseria meningitidis _serogroup C. The use of NeisVac-C should be determined on the basis of official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology There are no data on the use of different meningococcal group C conjugate vaccines within the primary series or for boosting. Whenever possible, the same vaccine should be used throughout. _Primary immunisation_ Infants from 2 months of age up to 12 months: Two doses, each of 0.5 ml, should be given with an interval of at least two months. (See sections 4.5 and 5.1 regarding co-administration of NeisVac-C with other vaccines.) Children one year of age and older, adolescents and adults: a single 0.5 ml dose. _Booster doses_ It is recommended that a booster dose should be given after completion of the primary immunisation series in infants. The timing of this dose should be in accordance with available offici Preberite celoten dokument